Figure S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia Andreas Varkaris , Ermira Pazolli , Hakan Gunaydin , Qi Wang , Levi Pierce , Alessandro A. Boezio , Artemisa Bulku , Lucian DiPietro , Cary Fridrich , Adam Frost , Fabrizio Giordanetto , Erika P. Hamilton , Katherine Harris , Michael Holliday , Tamieka L. Hunter , Amanda Iskandar , Yongli Ji , Alexandre Larivée , Jonathan R. LaRochelle , André Lescarbeau , Fabien Llambi , Brenda Lormil , Mary M. Mader , Brenton G. Mar , Iain Martin , Thomas H. McLean , Klaus Michelsen , Yakov Pechersky , Erika Puente-Poushnejad , Kevin Raynor , Dipali Rogala , Ramin Samadani , Alison M. Schram , Kelley Shortsleeves , Sweta Swaminathan , Shahein Tajmir , Gege Tan , Yong Tang , Roberto Valverde , Bryan Wehrenberg , Jeremy Wilbur , Bret R. Williams , Hongtao Zeng , Hanmo Zhang , W. Patrick Walters , Beni B. Wolf , David E. Shaw , Donald A. Bergstrom , James Watters , James S. Fraser , Pascal D. Fortin , D. Randal Kipp crossref（2024）
摘要
In vitro kinome profile of RLY-2608. RLY-2608 was tested at a concentration of 10 µM by SelectScreen (ThermoFisher Scientific)
更多 查看译文
AI 理解论文
溯源树
样例
